8-K: Butterfly Network Reports Q4 2023 Results, Exceeds Revenue Expectations and Launches New iQ3 Device

Butterfly Network announced its fourth quarter and full year 2023 financial results, exceeding revenue expectations, completing significant cost reductions, and launching its next-generation iQ3 ultrasound device.

Summary

• Butterfly Network reported a total revenue of $16.5 million for the fourth quarter of 2023, a decrease from $19.0 million in the same period of 2022.
• U.S. revenue decreased by 3% year-over-year to $10.9 million, while international sales declined by 24% to $4.6 million.
• Product revenue was $10.2 million, down 20% year-over-year, while software and other services revenue remained flat at $6.4 million.
• The company experienced a gross loss of $12.5 million, compared to a gross profit of $9.6 million in the prior year, primarily due to a $21.9 million inventory write-down.
• Adjusted gross profit was $9.4 million, and adjusted gross margin was 56.6%.
• Operating expenses decreased by 42% to $34.2 million, and adjusted EBITDA loss was $15.7 million, compared to $27.7 million in the prior year.
• The company completed a $170 million cost reduction and reorganization, reducing annual cash burn to approximately $60 million.
• Butterfly Network launched its third-generation point-of-care ultrasound system, Butterfly iQ3, in early 2024, ahead of schedule.
• The company anticipates low double-digit revenue growth and an adjusted EBITDA loss between $50 million and $60 million for fiscal year 2024.
• Cash, cash equivalents, and restricted cash were $138.7 million as of December 31, 2023.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the better-than-expected revenue, successful launch of the iQ3 device, and significant cost reductions. However, the net loss and year-over-year revenue decline temper the overall positive outlook.

Positives

• The launch of the Butterfly iQ3 device ahead of schedule is a positive development.
• The significant cost reduction and reorganization efforts have reduced annual cash burn, extending the company's cash runway into 2026.
• The increase in adjusted gross margin indicates improved profitability in core operations.
• The company's partnerships and expansion of the Butterfly Garden ecosystem are expected to drive future growth.
• The company is forecasting low double-digit revenue growth for fiscal year 2024.

Negatives

• Total revenue decreased year-over-year in the fourth quarter of 2023.
• The company reported a gross loss of $12.5 million due to a significant inventory write-down.
• International sales declined by 24% year-over-year.
• The company experienced a net loss of $44.1 million for the quarter.

Risks

• The company's ability to achieve its revenue growth targets for 2024 is subject to market conditions and adoption rates of its products.
• The company's financial performance is dependent on its ability to manage costs and maintain profitability.
• The company faces competition from other medical imaging companies.
• The company's success is dependent on its ability to maintain regulatory approvals for its products.
• The company's future performance is subject to various risks and uncertainties, including those related to product development, market acceptance, and regulatory changes.

Future Outlook

Butterfly Network anticipates low double-digit revenue growth and an adjusted EBITDA loss between $50 million and $60 million for fiscal year 2024. The company is also focused on expanding its product offerings, partnerships, and international presence.

Management Comments

• Joseph DeVivo, Butterfly's Chairman and CEO, stated that 2023 was a transition year focused on rightsizing the business and refocusing product and growth strategy.
• DeVivo also mentioned that the company invested in and launched products and applications that will propel growth initiatives.
• Management is confident in the company's growth prospects for 2024 and beyond.

Industry Context

The announcement reflects a broader trend in the medical device industry towards portable and accessible diagnostic tools. Butterfly Network's focus on semiconductor-based ultrasound technology aligns with the increasing demand for cost-effective and innovative healthcare solutions. The company's partnerships and educational offerings also indicate a strategic approach to market penetration and adoption.

Comparison to Industry Standards

• Butterfly Network's adjusted gross margin of 56.6% is comparable to other medical device companies, but the GAAP gross margin was significantly impacted by a large inventory write-down.
• The company's focus on cost reduction and efficiency improvements is a common strategy in the medical device industry, particularly for companies in the growth phase.
• Competitors like Philips and GE Healthcare offer more traditional ultrasound systems, while Butterfly focuses on handheld, portable devices. Butterfly's technology is unique in its use of semiconductor technology.
• The company's partnerships with companies like Mendaera and Forest Neurotech are similar to other medical device companies that collaborate to expand their product offerings and market reach.
• The launch of the iQ3 device is a significant step in competing with more established players in the ultrasound market.

Stakeholder Impact

• Shareholders may view the results positively due to the better-than-expected revenue and cost reductions.
• Employees may be impacted by the cost reduction and reorganization efforts.
• Customers will benefit from the launch of the new iQ3 device and expanded educational offerings.
• Partners will benefit from the company's growing ecosystem and collaborative agreements.
• Creditors will be impacted by the company's financial performance and cash position.

Next Steps

• Butterfly Network will host an Investor Day on March 18, 2024, to share more about its growth initiatives.
• The company will continue to focus on expanding its product offerings, partnerships, and international presence.
• The company will work to achieve its revenue growth targets for fiscal year 2024.

Key Dates

Keywords

ultrasound, medical imaging, digital health, point-of-care, semiconductor, Butterfly iQ3, revenue, cost reduction, EBITDA, FDA clearance